
    
      This is a Phase 2a, double-blind, placebo-controlled, multicentre, adaptive design study of
      BLD-2660 in subjects with IPF. The study will include a Screening period, a Treatment period,
      and a Follow-up period. Data on PK, PD, and biomarker activity will be observed.
    
  